NCT06283524Completed
Eye-tracking Investigation of Clinical Measures in Multiple Sclerosis
Source: ClinicalTrials.gov · Last updated 1 Apr 2026
Brief summary (registry, in English)
The overarching goal of this research protocol is to acquire eye-tracking, cognitive, and disease-severity metrics in MS patients to train machine learning algorithms that will support the development and performance assessment of a sensitive and non-invasive eye-tracking software application. The training of our machine learning classifying algorithms to identify which eye-tracking metrics-or combination thereof-can serve as reliable markers of MS disease severity and cognitive status.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 200 (actual)
- First submitted
- 21 Feb 2024
- Start date
- 18 Mar 2024
- Primary completion date
- 18 Oct 2025
- Lead sponsor
- Innodem Neurosciences
- Diseases
- Multiple sclerosis
- NCT number
- NCT06283524
What you commit to
- Study type: Observational
- Participants enrolled: 200
- From 18 Mar 2024 to the primary completion date, 18 Oct 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Having started a new prescription medication or having changed the dose of a medication known to influence ocular motor visual function (e.g. benzodiazepines, antipsychotics and anticonvulsants) within the past three months
Other illness
- Evidence or medical history of psychiatric issues, which are known to also affect movements and oculomotor control
- Presence of comorbid neurological conditions to avoid eye movement anomaly confounds (Strabismus, cranial nerve palsy, stroke-causing hemianopsia)
- Diagnosis of macular edema or other pre-existing ocular conditions that would prevent a participant from performing the eye movement assessments
- Participants with non-disease related physical impairments to a leg, hand, or arm (e.g., broken bone or severe sprain) that would not allow completion of the assessments
Who the study is looking for
- Able to provide informed consent
- Aged 18 years or older at the time of enrollment
- Able to read in either French or English
- Able to read the oculomotor task on-screen instructions at the testing distance (45cm) with or without corrective lenses
- Confirmed diagnosis of MS as per the Macdonald criteria, irrespective of MS subtype (relapsing-remitting (RRMS), secondary-progressive (SPMS), primary-progressive (PPMS), and progressive-relapsing (PRMS))
- Neurologist-determined EDSS score between 1.0-8.0
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Genge Partners Inc. Coordinator of this site? Confirm its status | Montreal | Canada | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.